STRO

STRO

USD

Sutro Biopharma Inc. Common Stock

$0.903-0.337 (-27.210%)

वास्तविक समय मूल्य

Healthcare
जैव प्रौद्योगिकी
संयुक्त राज्य अमेरिका

मूल्य चार्ट

मुख्य मीट्रिक्स

बाजार मीट्रिक्स
कंपनी के मौलिक सिद्धांत
ट्रेडिंग आँकड़े

बाजार मीट्रिक्स

खुलना

$1.240

उच्च

$1.240

कम

$0.832

मात्रा

0.05M

कंपनी के मौलिक सिद्धांत

बाजार पूंजीकरण

108.9M

उद्योग

जैव प्रौद्योगिकी

देश

United States

ट्रेडिंग आँकड़े

औसत मात्रा

1.76M

एक्सचेंज

NGM

मुद्रा

USD

52-सप्ताह रेंज

कम $0.52वर्तमान $0.903उच्च $5.17

संबंधित समाचार

Analyst Upgrades

HC Wainwright & Co. Downgrades Sutro Biopharma to Neutral, Lowers Price Target to $2

HC Wainwright & Co. analyst Andrew Fein downgrades Sutro Biopharma from Buy to Neutral and lowers the price target from $12 to $2.

और देखें
HC Wainwright & Co. Downgrades Sutro Biopharma to Neutral, Lowers Price Target to $2
GlobeNewswire

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

SOUTH SAN FRANCISCO, Calif., March 15, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs),

और देखें
Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025
Analyst Upgrades

Citizens Capital Markets Downgrades Sutro Biopharma to Market Perform

Citizens Capital Markets analyst Reni Benjamin downgrades Sutro Biopharma from Market Outperform to Market Perform.

और देखें
Citizens Capital Markets Downgrades Sutro Biopharma to Market Perform
Analyst Upgrades

Wedbush Downgrades Sutro Biopharma to Neutral, Lowers Price Target to $2

Wedbush analyst David Nierengarten downgrades Sutro Biopharma from Outperform to Neutral and lowers the price target from $8 to $2.

और देखें
Wedbush Downgrades Sutro Biopharma to Neutral, Lowers Price Target to $2
Analyst Upgrades

B of A Securities Downgrades Sutro Biopharma to Underperform, Lowers Price Target to $1

B of A Securities analyst Tazeen Ahmad downgrades Sutro Biopharma from Buy to Underperform and lowers the price target from $11 to $1.

और देखें
B of A Securities Downgrades Sutro Biopharma to Underperform, Lowers Price Target to $1
GlobeNewswire

Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights

– Sutro announced a strategic portfolio review resulting in prioritization of wholly-owned next-generation ADC programs; Key management changes announced as part of transition – – Cash, cash equivalents and marketable

GlobeNewswire

Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug

अपडेट रहें

मूल्य अलर्ट सेट करें, AI विश्लेषण अपडेट और वास्तविक समय बाजार समाचार प्राप्त करें।